The COVID-19 epidemic in Madagascar: clinical description and laboratory results of the first wave, march-september 2020.
COVID-19
SARS-CoV-2
Surveillance
epidemiology
madagascar
pandemic
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
25
01
2021
received:
30
12
2020
accepted:
29
01
2021
pubmed:
16
2
2021
medline:
22
6
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Following the first detection of SARS-CoV-2 in passengers arriving from Europe on 19 March 2020, Madagascar took several mitigation measures to limit the spread of the virus in the country. Nasopharyngeal and/or oropharyngeal swabs were collected from travellers to Madagascar, suspected SARS-CoV-2 cases and contact of confirmed cases. Swabs were tested at the national reference laboratory using real-time RT-PCR. Data collected from patients were entered in an electronic database for subsequent statistical analysis. All distribution of laboratory-confirmed cases were mapped, and six genomes of viruses were fully sequenced. Overall, 26,415 individuals were tested for SARS-CoV-2 between 18 March and 18 September 2020, of whom 21.0% (5,553/26,145) returned positive. Among laboratory-confirmed SARS-CoV-2-positive patients, the median age was 39 years (IQR: 28-52), and 56.6% (3,311/5,553) were asymptomatic at the time of sampling. The probability of testing positive increased with age with the highest adjusted odds ratio of 2.2 [95% CI: 1.9-2.5] for individuals aged 49 years and more. Viral strains sequenced belong to clades 19A, 20A and 20B indicative of several independent introduction of viruses. Our study describes the first wave of the COVID-19 in Madagascar. Despite early strategies in place Madagascar could not avoid the introduction and spread of the virus. More studies are needed to estimate the true burden of disease and make public health recommendations for a better preparation to another wave.
Sections du résumé
BACKGROUND
Following the first detection of SARS-CoV-2 in passengers arriving from Europe on 19 March 2020, Madagascar took several mitigation measures to limit the spread of the virus in the country.
METHODS
Nasopharyngeal and/or oropharyngeal swabs were collected from travellers to Madagascar, suspected SARS-CoV-2 cases and contact of confirmed cases. Swabs were tested at the national reference laboratory using real-time RT-PCR. Data collected from patients were entered in an electronic database for subsequent statistical analysis. All distribution of laboratory-confirmed cases were mapped, and six genomes of viruses were fully sequenced.
RESULTS
Overall, 26,415 individuals were tested for SARS-CoV-2 between 18 March and 18 September 2020, of whom 21.0% (5,553/26,145) returned positive. Among laboratory-confirmed SARS-CoV-2-positive patients, the median age was 39 years (IQR: 28-52), and 56.6% (3,311/5,553) were asymptomatic at the time of sampling. The probability of testing positive increased with age with the highest adjusted odds ratio of 2.2 [95% CI: 1.9-2.5] for individuals aged 49 years and more. Viral strains sequenced belong to clades 19A, 20A and 20B indicative of several independent introduction of viruses.
CONCLUSIONS
Our study describes the first wave of the COVID-19 in Madagascar. Despite early strategies in place Madagascar could not avoid the introduction and spread of the virus. More studies are needed to estimate the true burden of disease and make public health recommendations for a better preparation to another wave.
Identifiants
pubmed: 33586912
doi: 10.1111/irv.12845
pmc: PMC8013501
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-468Subventions
Organisme : NCIRD CDC HHS
ID : U51 IP000812
Pays : United States
Organisme : World Health Organization
Pays : International
Organisme : NCIRD CDC HHS
ID : U5/IP000812-05
Pays : United States
Informations de copyright
© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
PLoS One. 2015 Feb 23;10(2):e0117919
pubmed: 25706531
Swiss Med Wkly. 2020 Aug 11;150:w20331
pubmed: 32799308
Open Forum Infect Dis. 2020 Sep 18;7(11):ofaa434
pubmed: 33200080
J Med Microbiol. 2020 Aug;69(8):1114-1123
pubmed: 32783802
BMJ. 2020 Apr 6;369:m1401
pubmed: 32253175
Nat Med. 2020 Jul;26(7):999-1003
pubmed: 32528154
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
Am J Emerg Med. 2021 Aug;46:476-481
pubmed: 33189517
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
PLoS One. 2012;7(5):e37067
pubmed: 22615893
Influenza Other Respir Viruses. 2019 Mar;13(2):138-147
pubmed: 30596225
PLoS One. 2018 Nov 21;13(11):e0205124
pubmed: 30462659
Influenza Other Respir Viruses. 2015 May;9(3):101-9
pubmed: 25711873
Influenza Other Respir Viruses. 2021 May;15(3):407-412
pubmed: 33128444
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Clin Microbiol Infect. 2020 Sep;26(9):1236-1241
pubmed: 32502645
Int J Environ Res Public Health. 2020 Nov 04;17(21):
pubmed: 33158234
Int J Infect Dis. 2021 Feb;103:6-8
pubmed: 33217573
Bull World Health Organ. 2017 May 01;95(5):375-381
pubmed: 28479639
PLoS One. 2011 Mar 03;6(3):e17579
pubmed: 21390235
Influenza Other Respir Viruses. 2021 Jul;15(4):457-468
pubmed: 33586912
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
New Microbes New Infect. 2021 Jan;39:100822
pubmed: 33251017
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451367
BMC Health Serv Res. 2020 Sep 7;20(1):842
pubmed: 32894107
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508